Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: Kallikreins and prostate cancer

Cancer Prevention Research

Volumn 3, Issue 5, 2010, Pages 611-619

  Klein, Robert J ^a   Halldén, Christer ^b   Cronin, Angel M ^a   Ploner, Alexander ^c   Wiklund, Fredrik ^c   Bjartell, Anders S ^b   Stattin, Pär ^d   Xu, Jianfeng ^e   Scardino, Peter T ^a   Offit, Kenneth ^a   Vickers, Andrew J ^a   Grönberg, Henrik ^c   Lilja, Hans ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA MICROSEMINOPROTEIN; KALLIKREIN RELATED PEPTIDASE 2; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 19Q; CONTROLLED STUDY; DNA FLANKING REGION; GENE LOCUS; GENETIC MARKER; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN;

AREA UNDER CURVE; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KALLIKREINS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 77952026425     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0206     Document Type: Article

References (30)

1. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85. (Pubitemid 30451850)
2. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006;38:652-658.
3. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40:316-321. (Pubitemid 351311772)
4. Freedman ML, Haiman CA, Patterson N, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006;103:14068-14073. (Pubitemid 44452981)
5. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008;40:281-283. (Pubitemid 351311771)
6. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39:977-983. (Pubitemid 47185170)
7. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008;40:310-315. (Pubitemid 351311773)
8. Lai J, Kedda MA, Hinze K, et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 2007;28:1032-1039. (Pubitemid 47072187)
9. Severi G, Hayes VM, Neufing P, et al. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Cancer Epidemiol Biomarkers Prev 2006;15:1142-1147.
10. Cicek MS, Liu X, Casey G, Witte JS. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11α in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 2005;14:2173-2177.
11. Nam RK, Zhang WW, Klotz LH, et al. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Clin Cancer Res 2006;12:6452-6458.
12. Ahn J, Berndt SI, Wacholder S, et al. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet 2008;40:1032-1034.
13. Eeles R, Giles G, Neal D, Muir K, Easton DF. Reply to "Variation in KLK genes, prostate-specific antigen and risk of prostate cancer". Nat Genet 2008;40:1035-1036.
14. Pal P, Xi H, Sun G, et al. Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin. Hum Genet 2007;122:251-259. (Pubitemid 47616533)
15. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-278. (Pubitemid 351430866)
16. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001;27:234-236.
17. Lindmark F, Zheng SL, Wiklund F, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004;96:1248-1254. (Pubitemid 39232716)
18. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358:910-919. (Pubitemid 351397090)
19. Varenhorst E, Garmo H, Holmberg L, et al. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol 2005;39:117-123.
20. Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Lovgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995;41:1115-1120.
21. Becker C, Piironen T, Kiviniemi J, Lilja H, Pettersson K. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 2000;46:198-206. (Pubitemid 30104243)
22. Vaisanen V, Eriksson S, Ivaska KK, Lilja H, Nurmi M, Pettersson K. Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem 2004;50:1607-1617. (Pubitemid 39121229)
23. Stranger BE, Forrest MS, Clark AG, et al. Genome-wide associations of gene expression variation in humans. PLoS Genet 2005;1:e78.
24. Purcell S, Daly MJ, Sham PC. WHAP: haplotype-based association analysis. Bioinformatics 2007;23:255-256.
25. Abrahamsson PA, Andersson C, Bjork T, et al. Radioimmunoassay of β-microseminoprotein, a prostatic-secreted protein present in sera of both men and women. Clin Chem 1989;35:1497-1503. (Pubitemid 19187853)
26. Nam RK, Reeves JR, Toi A, et al. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol 2006;175:1291-1297. (Pubitemid 43312972)
27. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-649. (Pubitemid 46676108)
28. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 2008;6:19.
29. Wellcome Trust Case-Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-678.
30. Nam RK, Zhang WW, Trachtenberg J, et al. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol 2003;21:2312-2319. (Pubitemid 46621869)